Standard BioTools Inc (LAB, Financial) is set to release its Q1 2025 earnings on May 6, 2025. The consensus estimate for Q1 2025 revenue is $40.10 million, and the earnings are expected to come in at -$0.08 per share. The full year 2025's revenue is expected to be $169.20 million, and the earnings are expected to be -$0.26 per share. More detailed estimate data can be found on the Forecast page.
Standard BioTools Inc (LAB, Financial) Estimates Trends
Revenue estimates for Standard BioTools Inc (LAB) have declined from $186.93 million to $169.20 million for the full year 2025 and declined from $224.21 million to $190.80 million for 2026 over the past 90 days. Earnings estimates have declined from -$0.21 per share to -$0.26 per share for the full year 2025 and declined from -$0.09 per share to -$0.17 per share for 2026 over the past 90 days.
Standard BioTools Inc (LAB, Financial) Reported History
In the previous quarter ending on December 31, 2024, Standard BioTools Inc's (LAB) actual revenue was $46.72 million, which beat analysts' revenue expectations of $43.03 million by 8.56%. Standard BioTools Inc's (LAB) actual earnings were -$0.09 per share, which missed analysts' earnings expectations of -$0.07 per share by -28.57%. After releasing the results, Standard BioTools Inc (LAB) was down by -10.68% in one day.
Standard BioTools Inc (LAB, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 2 analysts, the average target price for Standard BioTools Inc (LAB) is $2.38, with a high estimate of $2.50 and a low estimate of $2.25. The average target implies an upside of 97.92% from the current price of $1.20.
Based on GuruFocus estimates, the estimated GF Value for Standard BioTools Inc (LAB, Financial) in one year is $0.82, suggesting a downside of -31.67% from the current price of $1.20.
Based on the consensus recommendation from 3 brokerage firms, Standard BioTools Inc's (LAB, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
